421 related articles for article (PubMed ID: 9218101)
1. New drugs in essential thrombocythemia and polycythemia vera.
Tefferi A; Elliott MA; Solberg LA; Silverstein MN
Blood Rev; 1997 Mar; 11(1):1-7. PubMed ID: 9218101
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic options for essential thrombocythemia and polycythemia vera.
Solberg LA
Semin Oncol; 2002 Jun; 29(3 Suppl 10):10-5. PubMed ID: 12096352
[TBL] [Abstract][Full Text] [Related]
3. Anagrelide for control of thrombocytosis due to myeloproliferative disorders.
Harrison CN
Future Oncol; 2005 Oct; 1(5):609-18. PubMed ID: 16556037
[TBL] [Abstract][Full Text] [Related]
4. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
Gilbert HS
Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
[TBL] [Abstract][Full Text] [Related]
5. Other secondary sequelae of treatments for myeloproliferative disorders.
Gilbert HS
Semin Oncol; 2002 Jun; 29(3 Suppl 10):22-7. PubMed ID: 12096354
[TBL] [Abstract][Full Text] [Related]
6. Anagrelide for thrombocytosis in myeloproliferative disorders: a prospective study to assess efficacy and adverse event profile.
Steurer M; Gastl G; Jedrzejczak WW; Pytlik R; Lin W; Schlögl E; Gisslinger H
Cancer; 2004 Nov; 101(10):2239-46. PubMed ID: 15476273
[TBL] [Abstract][Full Text] [Related]
7. [Chronic myeloproliferative diseases].
Sréter L
Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
[TBL] [Abstract][Full Text] [Related]
8. Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.
Michiels JJ; Barbui T; Finazzi G; Fuchtman SM; Kutti J; Rain JD; Silver RT; Tefferi A; Thiele J
Leuk Lymphoma; 2000 Jan; 36(3-4):239-53. PubMed ID: 10674896
[TBL] [Abstract][Full Text] [Related]
9. Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
Hultdin M; Sundström G; Wahlin A; Lundström B; Samuelsson J; Birgegård G; Engström-Laurent A
Med Oncol; 2007; 24(1):63-70. PubMed ID: 17673813
[TBL] [Abstract][Full Text] [Related]
10. Alpha-2a interferon therapy and antibody formation in patients with essential thrombocythemia and polycythemia vera with thrombocytosis.
Törnebohm-Roche E; Merup M; Lockner D; Paul C
Am J Hematol; 1995 Mar; 48(3):163-7. PubMed ID: 7864024
[TBL] [Abstract][Full Text] [Related]
11. Anagrelide hydrochloride and ruxolitinib for treatment of polycythemia vera.
Kremyanskaya M; Mascarenhas J; Hoffman R
Expert Opin Pharmacother; 2015 Jun; 16(8):1185-94. PubMed ID: 25873215
[TBL] [Abstract][Full Text] [Related]
12. Modern treatment strategies in polycythemia vera.
Gilbert HS
Semin Hematol; 2003 Jan; 40(1 Suppl 1):26-9. PubMed ID: 12682879
[TBL] [Abstract][Full Text] [Related]
13. A phase II trial of pegylated interferon alpha-2b therapy for polycythemia vera and essential thrombocythemia: feasibility, clinical and biologic effects, and impact on quality of life.
Samuelsson J; Hasselbalch H; Bruserud O; Temerinac S; Brandberg Y; Merup M; Linder O; Bjorkholm M; Pahl HL; Birgegard G;
Cancer; 2006 Jun; 106(11):2397-405. PubMed ID: 16639737
[TBL] [Abstract][Full Text] [Related]
14. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
Barbui T
Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
[TBL] [Abstract][Full Text] [Related]
15. A clinical update in polycythemia vera and essential thrombocythemia.
Tefferi A; Solberg LA; Silverstein MN
Am J Med; 2000 Aug; 109(2):141-9. PubMed ID: 10967156
[TBL] [Abstract][Full Text] [Related]
16. A critical review of anagrelide therapy in essential thrombocythemia and related disorders.
Dingli D; Tefferi A
Leuk Lymphoma; 2005 May; 46(5):641-50. PubMed ID: 16019501
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness considerations in the treatment of essential thrombocythemia.
Golub R; Adams J; Dave S; Bennett CL
Semin Oncol; 2002 Jun; 29(3 Suppl 10):28-32. PubMed ID: 12096355
[TBL] [Abstract][Full Text] [Related]
18. Use of pegylated interferon in young patients with polycythemia vera and essential thrombocythemia.
Kucine N; Bergmann S; Krichevsky S; Jones D; Rytting M; Jain J; Bennett CM; Resar LMS; Mascarenhas J; Verstovsek S; Hoffman R
Pediatr Blood Cancer; 2021 Mar; 68(3):e28888. PubMed ID: 33381905
[TBL] [Abstract][Full Text] [Related]
19. Anagrelide: a new drug for treating thrombocytosis.
Silverstein MN; Petitt RM; Solberg LA; Fleming JS; Knight RC; Schacter LP
N Engl J Med; 1988 May; 318(20):1292-4. PubMed ID: 3362187
[TBL] [Abstract][Full Text] [Related]
20. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Nand S; Stock W; Godwin J; Fisher SG
Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]